Research Paper Volume 11, Issue 22 pp 10610—10625

Ets2 suppresses inflammatory cytokines through MAPK/NF-κB signaling and directly binds to the IL-6 promoter in macrophages

class="figure-viewer-img"

Figure 4. Ets2 inhibits LPS-induced IL-6 and TNF-α production and improves the survival of CLP-induced sepsis in vivo. (A, B) ELISA assay of IL-6 (A) and TNF-α (B) in the serum of Ets2fl/flLyz2cre or Ets2fl/flLyz2cre+ mice, intraperitoneally injected with LPS (1 μg/g body weight) for 5 h (n=3 per phenotype). (C, D) ELISA assay of IL-6 (C) and TNF-α (D) in the serum of Ets2fl/flLyz2cre or Ets2fl/flLyz2cre+ mice at 6 h after CLP surgery (n=4 per phenotype). (EG) Continuous IL-6 (E) and TNF-α (F) at postoperative day 1, 3, 5, 7, and survival rate (G) of Ets2fl/flLyz2cre or Ets2fl/flLyz2cre+ mice given CLP or Sham surgery (n=10 per phenotype). Data are shown as the mean ± s.e.m. Student’s t-test compared with the Ets2fl/flLyz2cre- group for ELISA experiments. A log-rank test was used for survival data. *, P<0.05.